Literature DB >> 19640329

Serum levels of p53 and cytochrome c in subjects with type 2 diabetes and impaired glucose tolerance.

Yildiz Dincer1, Solen Himmetoglu, Serap Yalin, Taner Damci, Hasan Ilkova, Tulay Akcay.   

Abstract

PURPOSE: To examine apoptotic markers in serum of subjects with diabetes and impaired glucose tolerance (IGT). Serum levels of p53 and cytochrome c, regulator molecules for apoptosis, were measured in subjects with type 2 diabetes, subjects with IGT and healthy controls.
METHODS: Forty one subjects with type 2 diabetes, 27 with IGT and 27 healthy volunteers were included in the study. Serum level of cytochrome c and p53 were measured with competitive ELISA.
RESULTS: Serum levels of p53 were lower in the group of subjects with type 2 diabetes (085+/-0.39 U/ml) than in controls (1.09+/-0.49 U/ml) (P < 0.05) and in the subjects with IGT (0.98+/-0.37 U/ml) (P < 0.05). There was no significant difference between the group with IGT and controls. Also, there was no difference for serum level of cytochrome c among the groups. In the group of subjects with type 2 diabetes, serum level of cytochrome c was mildly correlated with HbA1c (r:0.39, P < 0.05).
CONCLUSION: The present study shows that the serum level of p53 is lower in the patients with type 2 diabetes than in controls or in subjects with IGT. No difference was seen among the the groups for the serum level of cytochrome c.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19640329     DOI: 10.25011/cim.v32i4.6617

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  2 in total

Review 1.  Is p53 Involved in Tissue-Specific Insulin Resistance Formation?

Authors:  Justyna Strycharz; Jozef Drzewoski; Janusz Szemraj; Agnieszka Sliwinska
Journal:  Oxid Med Cell Longev       Date:  2017-01-17       Impact factor: 6.543

2.  Tumour protein 53 is linked with type 2 diabetes mellitus.

Authors:  Agnieszka Sliwinska; Jacek Kasznicki; Marcin Kosmalski; Melania Mikolajczyk; Aneta Rogalska; Karolina Przybylowska; Ireneusz Majsterek; Jozef Drzewoski
Journal:  Indian J Med Res       Date:  2017-08       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.